Document:

Form 10-K 2010 Exhibit 10.32

Exhibit 10.32

NON-EXCLUSIVE LICENSE AGREEMENT

THIS AGREEMENT, entered into and effective as of the 21st day of December, 2010 (the
"Effective Date"), by and between MMRGlobal, Inc., a Delaware corporation (hereinafter
"MMRGLOBAL"), having an address at 4401 Wilshire Blvd., Second Floor, Los Angeles, CA 90010 and
Celgene Corporation, a Delaware company (together with its subsidiaries and affiliates hereinafter collectively referred
to as "CELGENE"), having an address at 86 Morris Avenue, Summit, NJ 07901 (each a "Party,"
collectively the "Parties").

WHEREAS, MMRGLOBAL owns certain clinical and scientific data relating to targeted
immunotherapies for cancer and other disease treatments to stimulate a patient's immune response and other Confidential
Information.

WHEREAS, CELGENE desires to obtain access to and use such data and other Confidential
Information for the limited purpose of expediting U.S. Food and Drug Administration ("FDA") or other similar
government regulatory agencies' approval of and the bringing to market of the CELGENE product Revlimid® (lenalidomide)
("the Product") for the first line treatment of follicular lymphoma (the "Field").

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth,
the Parties agree as follows:

ARTICLE 1. GRANT OF LICENSES

1.1   MMRGLOBAL hereby grants to CELGENE and CELGENE hereby accepts, on and subject to
the terms and conditions of this Agreement, a world-wide, non-exclusive license, without the right to sublicense or otherwise
transfer, for the term of this Agreement, to access and use the Data Set (as defined below) for the limited purpose of
expediting FDA approval and bringing to market the Product by providing a surrogate endpoint in follicular lymphoma (the
"Surrogate Endpoints") based on the information contained in the Data Set (as defined below).  The validation of
the surrogacy implies demonstration that the treatment effects on the Surrogate Endpoint shall predict treatment effects on the
true endpoint of Progression Free Survival ("PFS").  This shall, in turn, expedite regulatory agency approval of the
use of the Product in the Field (the "Purpose").  "Data Set," as used herein, means the
clinical and scientific data relating to targeted immunotherapies for cancer and other disease treatments, including data and
other information from the Phase III clinical trials of MMRGLOBAL's pre-Merger company Favrille, Inc.

1.2   Other than to the extent required by the FDA and other similar government regulatory agencies to
reference, access, and/or cite portions of the Data Set, as reasonably required to comply with regulatory requirements, the
non-exclusive license granted to CELGENE herein shall not include the right to distribute the Data Set in any manner.  For the
purposes of clarity, Celgene shall have the right to, based on the meta-analysis, publish findings, results and conclusions
based on the information contained in the Data Set and all appropriate and necessary bibliographical references
thereto.

ARTICLE 2. OBLIGATIONS OF THE PARTIES

2.1   Promptly after the Effective Date, MMRGLOBAL will make the Data Set and other
Confidential Information available to an independent statistician or researcher for purposes of

MMR-Celgene Corporation Non-Exclusive License Agreement — CONFIDENTIAL  

  

[***]: Certain  confidential information contained in this document marked with [***] has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

accessing, reviewing and cataloguing the Data Set and other Confidential Information provided by MMRGLOBAL pursuant to this Agreement
("Independent Consultant").  The Data Set and other Confidential Information provided to the Independent
Consultant shall include access to the Favrille, Inc. computer server, and physical documents relating to the Data Set,
including boxes from an off-site storage facility.  The Independent Consultant will access the database, and upon verification
from the Independent Consultant that the Data Set exists such that it is sufficient, in the sole and exclusive opinion of the
Independent Consultant, to achieve the Purpose, MMRGLOBAL shall provide the Independent Consultant an electronic
version/copy of the portion of the Data Set applicable to the Purpose.  The access to the applicable portion of the Data Set will
be restricted to the Independent Consultant and an academic expert statistician  ("Independent Statistician") in their
usual working environment.

2.2   The Parties will employ the Independent Consultant.  CELGENE will provide MMRGLOBAL with
names of proposed Independent Consultants and MMRGLOBAL will have the right to approve a particular Independent
Consultant, such approval not to be unreasonably withheld by MMRGLOBAL.  MMRGLOBAL shall make best efforts to
accommodate all reasonable requests that relate to access to the Data Set, including access to a copy of specific data points
which shall be selected from the Data Set for use in a meta-analysis consistent with Section 2.1.  The Independent
Consultant, Independent Statistician and/or CELGENE may not otherwise duplicate any other portions of the Data Set, except
as explicitly set forth herein.  Upon completion of use of said data points, CELGENE shall destroy any and all copies of such
portions of the Data Set created and provide proof or certification of the destruction to MMRGLOBAL.

2.3   MMRGLOBAL will establish and maintain a secure room at 4401 Wilshire Blvd., Second Floor, Los
Angeles, CA 90010 for the Independent Consultant to access, review and catalogue the Data Set and other Confidential
Information pursuant to the Purpose of this Agreement.

2.4   CELGENE will bear the costs incurred by the Parties to:  (a) employ the Independent
Consultant and Independent Statistician; (b) provide for secure transfer and/or reproduction of the Data Set and other
Confidential Information, to the extent expressly permitted pursuant to this Agreement; and (c) any other expenses
the Parties agree are reasonably necessary to effectuate the Purpose of this Agreement.  The Parties agree that to the extent
applicable, CELGENE may provide any necessary equipment and/or resources as required pursuant to this Article
2.

ARTICLE 3. CONSULTATION AND REPORTS

3.1   CELGENE shall provide MMRGLOBAL with the following reports and/or updates relating to
this Agreement:

	Upon access to the Data Set, a report from the Independent Consultant verifying the existence
and, in the opinion of the Independent Consultant, that the Data Set can be used to achieve the Purpose.  The Independent
Consultant shall complete the review of the Data Set and provide his/her opinion pursuant to this Subsection 3.1(a)
within forty-five (45) business days of the Effective Date of this Agreement.  (The opinion of the Independent Consultant based
on, among other things, the existence of information, to the extent it is available from the Favrille, Inc. Phase III clinical trials,
such as type of patients (relapsed, refractory, untreated), patient demographics (age, sex), lymphoma baseline assessment,
treatments, criteria for response and disease progression, treatment arm, date of randomization, best response, date of best
response (if responder), first

MMR-Celgene Corporation Non-Exclusive License Agreement — CONFIDENTIAL  

  

[***]: Certain  confidential information contained in this document marked with [***] has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

response (if responder), date of first response (if responder), response assessment by a central
radiology review, complete response (CR) status at 12, 24, 30 months, date of progression, date of death (if available), date of
last observation and/or status of the last observation).  In the event the Independent Consultant concludes the Data Set does
not exist consistent with the representations and warranties set forth in this Agreement or is insufficient to achieve the Purpose,
MMRGLOBAL shall have the opportunity to assist the Independent Consultant to identify and/or locate any additional
necessary information, including providing portions of the Data Set in electronic format (access to such may require the Parties
to mutually agree to extend the forty-five (45) day review/opinion period of this Subsection 3.1(a) to the extent
reasonably necessary).

	Advise, in advance, as to timing of the relevant meetings (regarding the Surrogate Endpoints)
and/or submissions with or to FDA and other similar government regulatory agencies.

3.2   All reports and other work product created under this Agreement shall be deemed Confidential
Information and shall not be shared with any third parties not contemplated in this Agreement.  Notwithstanding the foregoing,
CELGENE shall have the right to share, as appropriate, with FDA and similar government regulatory agencies for the
Purposes contemplated and discussed herein.

ARTICLE 4. MILESTONE PAYMENTS

4.1   Milestone Payments.  CELGENE shall make the following one-time milestone payments to
MMRGLOBAL:

	Within ten (10) business days of the Effective Date, a fee of [***]  (US$[***]) ("First Milestone
Payment"); and

	Within ten (10) business days of CELGENE receiving confirmation from the Independent
Consultant that the Data Set is sufficient and the information contained therein may be used to articulate and support the
Purpose, a fee of [***]  (US$[***]) ("Second Milestone Payment").  Pursuant to Subsection 3.1(a), the
Independent Consultant shall provide such confirmation to CELGENE within forty-five (45) business days of the Effective Date.
If the Independent Consultant is unable, in the above mentioned forty-five (45) business days, to confirm that the Data Set is
sufficient and the information contained therein may be used to support the Purpose the Parties shall work together in good
faith to resolve this issue, including, if needed, providing a time extension that meets the business needs of the Parties.  In the
event it is the conclusion of the Independent Consultant that the Data Set is not sufficient for the Purpose the obligations under
this Article 4 shall immediately terminate and CELGENE shall have no access to and/or receive no copies of the Data
Set.

	Within ten (10) business days of CELGENE'S presentation and/or submission to FDA of the
Surrogate Endpoint relying at least in part upon the Data Set, a fee of [***] (US$[***]) ("Third Milestone Payment").
CELGENE shall complete the FDA presentation and/or submission, triggering the Third Milestone Payment, by no later than
June 30, 2012.

	Within ten (10) business days of FDA's acceptance of CELGENE'S presentation and/or
submission to FDA of the Surrogate Endpoint relying at least in part upon the Data Set, a fee of [***]  (US$[***]) ("Fourth
Milestone Payment").  Acceptance shall mean

MMR-Celgene Corporation Non-Exclusive License Agreement — CONFIDENTIAL  

  

[***]: Certain  confidential information contained in this document marked with [***] has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

CELGENE'S good faith understanding and belief of FDA's acceptance (as
articulated at a meeting between CELGENE and FDA) of the Surrogate Endpoint as a regulatory endpoint in a Phase III clinical
trial for the Product in the Field.  In the event that said Acceptance does not occur MMRGLOBAL shall have the right to request
a copy of the FDA-produced minutes from that meeting in order to confirm the non-Acceptance.  Acceptance shall mean
CELGENE'S good faith understanding and belief of FDA's acceptance (as articulated at a meeting between CELGENE and
FDA) of the Surrogate Endpoint as a regulatory endpoint in a Phase III clinical trial for the Product in the Field.  In the event
that said Acceptance does not occur MMRGLOBAL shall have the right to request a copy of the FDA-produced minutes from
that meeting in order to confirm the non-Acceptance.  In the event FDA does not ACCEPT the Surrogate Endpoint all
remaining obligations under Article 4 shall immediately terminate.

	Within ten (10) business days of CELGENE receiving official confirmation from FDA of approval of
the use of the Product in the Field (relying on the Surrogate Endpoints) CELGENE shall make a one-time milestone payment
of [***]  (US$[***]) ("USA Approval Milestone").

	Within ten (10) business days of CELGENE receiving official confirmation from any foreign
regulatory agency (such as the EMA) of approval of the use of the Product in the Field (relying on the Surrogate Endpoints)
CELGENE shall make a one-time milestone payment of [***]  (US$[***]) ("Foreign Approval Milestone"),
provided, however, that said approval takes place within five (5) years of the confirmation from FDA of approval of the
use of the Product in the Field (relying on the Surrogate Endpoints).  For the purposes of clarity, CELGENE shall only be
obligated to pay one (1) Foreign Approval Milestone to MMRGLOBAL regardless of the number of foreign regulatory agencies
approve the use of the Product in the Field.

4.2   The Parties acknowledge and agree that the Milestone Payments discussed above are the sole
and exclusive payment contemplated under this Agreement.  The payment of the USA Approval Milestone or the Foreign
Approval Milestone or at such point when CELGENE informs MMRGLOBAL that CELGENE has elected in its sole and
exclusive discretion not to seek regulatory approval in the Field in any other locations contemplated in this Agreement shall
terminate all of CELGENE milestone payment obligations under this Agreement.  In the event that CELGENE then elects (and
receives) regulatory approval in a location contemplated in this Agreement, CELGENE shall be obligated to make the
appropriate Milestone Payment to MMRGLOBAL, provided it has not already been made.

4.3   Each payment to MMRGLOBAL hereunder will be made by wire transfer to MMRGLOBAL (as
provided by MMRGLOBAL TO CELGENE) with written notice of such wire transfer.

4.4   In consideration for MMRGLOBAL making its entire Data Set and other Confidential Information
available for review, CELGENE will pay MMRGLOBAL, in addition to the Milestone Payments, if applicable, good faith
remuneration, to be separately negotiated by the Parties, for any additional portions of the Data Set and/or Confidential
Information identified by the Independent Consultant and/or CELGENE as providing additional benefit and/or utility to
CELGENE, beyond the scope of the limited Purpose of this Agreement.  Such additional portions of the Data Set and/or
Confidential Information may include, but are not limited to, proprietary anti-CD20 antibodies, human tissue samples,
intellectual property assets, including license and/or

MMR-Celgene Corporation Non-Exclusive License Agreement — CONFIDENTIAL  

  

[***]: Certain  confidential information contained in this document marked with [***] has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

assignment rights to patent applications and/or patents.  To the extent
applicable, the Parties agree to use good faith and best business practices to bring such additional Data Set and/or
Confidential Information to the other Party's attention and enter into a subsequent agreement for such good faith
remuneration.

ARTICLE 5. TERM AND TERMINATION

5.1   The term of this Agreement shall expire on the date of the last milestone payment pursuant to
Section 4.1, unless the Agreement is terminated as provided in this Article.

5.2   MMRGLOBAL may terminate this Agreement upon at least thirty (30) day written notice to
CELGENE for any breach of its obligations or default under the payment obligations set forth in Article 4 of this
Agreement.

5.3   Upon termination or expiration of this Agreement, the following procedures shall apply:
(a) CELGENE shall destroy the Data Set and/or other Confidential Information obtained pursuant to this Agreement,
including any documents, notes and/or other tangible materials derived or created therefrom and all copies thereof, including
for example any such tangible materials created by or provided to either CELGENE, Independent Statistician and/or the
Independent Consultant; and (b) provide written notice to MMRGLOBAL certifying the complete destruction of the
Data Set and/or other Confidential Information obtained pursuant to this Agreement, including any documents, notes and/or
other tangible materials derived or created therefrom and all copies thereof.

5.4   The provisions of Articles 6 and Sections 7.1, 7.2, 7.6 and 7.7 shall survive expiration or
termination of this Agreement.  In addition, the expiration or termination of this Agreement will not relieve the Parties of any
obligations accruing prior to or upon such expiration or termination, including any provisions of Articles 3 and 4 and
Section 2.4.

ARTICLE 6. CONFIDENTIALITY

6.1   In order for the Parties to fully cooperate in the effort as set forth in this Agreement, it will be
necessary for MMRGLOBAL to disclose Confidential Information (as defined in the Parties' Non-Disclosure Agreement entered
into on September 16, 2010 as attached to this Agreement as Exhibit A), including the Data Set as defined herein and
the terms of this Agreement.  CELGENE will treat all Confidential Information with the highest degree of care, but in any event
not less than the same degree of care and means that CELGENE utilizes to protect and handle its own information of a similar
nature.

6.2   The Confidential Information will be disclosed only to the Independent Consultant and Independent
Statistician (CELGENE will ensure such Independent Consultant and Independent Statistician are under the same
confidentiality obligations as CELGENE) and those employees of CELGENE with a "need to know" who are
instructed and agree not to disclose the Confidential Information to any divisions of CELGENE other than the Revlimid
Lymphoma Project Team.  Notwithstanding the foregoing, CELGENE is permitted to disclose the necessary portions of
Confidential Information pursuant to Section 1.2 to FDA and other similar government regulatory agencies as required
pursuant to the Purpose of this Agreement.

6.3   Except as explicitly set forth herein, the terms and conditions of the Parties' Non-Disclosure
Agreement entered into on September 16, 2010 (as attached to this Agreement as

MMR-Celgene Corporation Non-Exclusive License Agreement — CONFIDENTIAL  

  

[***]: Certain  confidential information contained in this document marked with [***] has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Exhibit A) shall control the disclosure of Confidential Information and CELGENE'S limited use and obligations relating thereto.  Notwithstanding the
Parties' Non-Disclosure Agreement:  (a) CELGENE may disclose the Confidential Information to the FDA pursuant to
Section 1.2, provided that CELGENE provides MMRGLOBAL with advance written notice of the requirement and
takes reasonable measures to obtain confidential treatment thereof; (b) CELGENE agrees that during the term of this
Agreement and for a period of five (5) years thereafter it will hold in strict confidence and not disclose Confidential Information
to any third party, except as approved in writing by MMRGLOBAL, and will use the Confidential Information for no purpose
other than as explicitly permitted under this Agreement.

ARTICLE 7. MISCELLANEOUS

7.1   The Data Set and all other Confidential Information are and will remain the sole property of
MMRGLOBAL.  CELGENE will not at any time do or cause to be done any act contesting or in any way impairing any part of
MMRGLOBAL'S right, title and/or interest in the Data Set and/or other Confidential Information.

7.2    (a) The Parties represent and warrant that they:  (i) have the right to make conveyances
and grants in accordance with this Agreement; (ii) have the appropriate authority to enter into this Agreement; and
(iii) have and hold all necessary and appropriate licenses required in order to effectuate the Purpose.  It is expressly
understood, however, that in making the conveyances and grants under this Agreement, MMRGLOBAL MAKES NO
REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, AND ASSUMES NO RESPONSIBILITIES
WHATSOEVER WITH RESPECT TO:  THE PERFORMANCE, MERCHANTABILITY, OR FITNESS FOR PARTICULAR
PURPOSE OF ANY CONFIDENTIAL INFORMATION PROVIDED; THE SUITABIITY, COMPLETENESS OR ACCURACY OF
INFORMATION OR OTHER DATA PROVIDED IN CONNECTION WITH THIS AGREEMENT.

(b) MMRGLOBAL represents and warrants:  (i) the Data Set contains all available clinical
and scientific data (and related documentation regarding such data) collected by MMRGLOBAL's pre-Merger company
Favrille, Inc. relating to targeted immunotherapies for cancer and other disease treatments from the company's Phase III
clinical trials; and (ii) it has all necessary informed consents for further use of the Data Set in accordance with the
Purpose of this Agreement, applicable regulations, laws and guidelines.  Notwithstanding Section 7.2(a),
MMRGLOBAL represents and warrants the Data Set was accumulated with an SAS license and MMRGLOBAL will either
obtain a current SAS license and/or confirm right to use an existing SAS license from an existing third party consultant of the
company, which provides for all uses as contemplated herein.

7.3   This Agreement is personal to the Parties and is not assignable or otherwise transferable in whole
or in part, without the prior written consent of the non-assigning Party, which shall not be unreasonably withheld.  Pursuant to
the written consent of the non-assigning Party, a Party may assign or transfer this Agreement and all obligations and licenses
granted herein provided that the resulting assignee or successor in interest of a Party agrees separately in writing to meet all
the obligations of this Agreement.

7.4   Failure to enforce any provision, clause and/or paragraph of this Agreement by either of the
Parties shall not constitute a waiver of any term hereof by the Parties.

MMR-Celgene Corporation Non-Exclusive License Agreement — CONFIDENTIAL  

  

[***]: Certain  confidential information contained in this document marked with [***] has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

7.5   Severability.  If any provision, clause and/or paragraph of this Agreement is found by a proper
authority to be unenforceable or invalid, such unenforceability or invalidity shall not render this Agreement unenforceable or
invalid as a whole and, in such event, such provision, clause and/or paragraph shall be changed and interpreted so as to best
accomplish the objectives of such unenforceable or invalid provision, clause and/or paragraph within the limits of applicable
law or applicable court decisions.

7.6   (a) MMRGLOBAL SHALL DEFEND AND INDEMNIFY AGAINST, AND HOLD CELGENE AND
THEIR RESPECTIVE EMPLOYEES, DIRECTORS, OFFICERS AND AGENTS HARMLESS FROM, ANY LOSS, COST,
LIABILITY OR EXPENSE (INCLUDING COURT COSTS AND REASONABLE FEES OF ATTORNEYS AND OTHER
PROFESSIONALS) INCURRED FROM ANY CLAIM ARISING OR ALLEGED TO ARISE OUT THIS AGREEMENT RELATING
TO CELGENE'S USE OF THE DATA SET ACCORDING TO THE TERMS AND CONDITIONS SET FORTH HEREIN.
NOTWITHSTANDING THE FOREGOING, MMRGLOBAL SHALL NOT BE RESPONSIBLE TO DEFEND AND INDEMNIFY
AGAINST, AND HOLD CELGENE AND THEIR RESPECTIVE EMPLOYEES, DIRECTORS, OFFICERS AND AGENTS
HARMLESS FROM ANY CLAIMS RESULTING FROM CELGENE'S NEGLIGENCE, MALFEASANCE, OR BREACH OF THIS
AGREEMENT.

(b) EXCEPT TO THE EXTENT CAUSED BY A BREACH BY MMRGLOBAL OF ITS WARRANTIES
UNDER SECTION 7.2(a) ABOVE, CELGENE SHALL DEFEND AND INDEMNIFY AGAINST, AND HOLD
MMRGLOBAL AND THEIR RESPECTIVE EMPLOYEES, DIRECTORS, OFFICERS AND AGENTS HARMLESS FROM, ANY
LOSS, COST, LIABILITY OR EXPENSE (INCLUDING COURT COSTS AND REASONABLE FEES OF ATTORNEYS AND
OTHER PROFESSIONALS) INCURRED FROM ANY CLAIM ARISING OR ALLEGED TO ARISE OUT OF CELGENE'S USE
OF THE DATA SET AND/OR OTHER CONFIDENTIAL INFORMATION PURSUANT TO THIS
AGREEEMENT.

7.7   This Agreement shall be governed by and construed in accordance with the laws of the State of
Delaware, without reference to conflict of laws principles.  Without prejudice to any other rights or remedies available at law, in
equity or under terms of this Agreement, the prevailing Party in any court action pursuant to this Agreement shall be entitled to
recover its expenses, including court costs and reasonable fees of attorneys, incurred from such action.

7.8   The terms and conditions herein contained constitute the entire agreement between the Parties
and supersede all previous agreements and understandings, whether oral or written, between the Parties hereto with respect
to the subject matter hereof.

7.9   The Parties acknowledges that certain Confidential Information may be deemed to be material
non-public information.  In addition, the Parties acknowledge that the Securities Exchange Act of 1934, as amended, and the
rules and regulations of the Securities and Exchange Commission thereunder, restrict the ability to trade in securities while in
possession of material non-public information.  CELGENE acknowledges, and agrees, that:  (a) under federal
securities laws anyone who has received material, non-public information from an issuer of securities is prohibited from
purchasing or selling securities of that issuer and also prohibited from communicating the information to anyone else;
(b) such acts may result in criminal and/or civil liability; and (c) the Confidential Information may constitute
material, non-public information in relation to MMRGLOBAL, the securities of which are publicly traded.

MMR-Celgene Corporation Non-Exclusive License Agreement — CONFIDENTIAL  

  

[***]: Certain  confidential information contained in this document marked with [***] has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

7.10   Use of Party Names.  The Parties agree to provide the other Party advance written notice of any
promotional material, press release or the like where one Party uses the name of the other Party and/or discloses the
existence of this Agreement.  In the event one Party requests approval of the other Party's promotional material, press release
or the like, such approval shall  be granted, if at all, within two (2) business days.  The Parties acknowledge that the signing of
this Agreement is considered a "material event" for MMRGLOBAL, obligating the company to certain disclosures of
which MMRGLOBAL shall use reasonable business efforts to seek confidential treatment of its required disclosures relating to
the nature and terms of this Agreement.

7.11   All notices, reports or other communications required or permitted under this Agreement shall be in
writing and shall be delivered by personal delivery, electronic mail, facsimile transmission or by certified or registered mail,
return receipt requested, and shall be deemed given upon personal delivery, five (5) days after deposit in the mail, or upon
acknowledgment of receipt of electronic transmission.  Notices shall be sent to the addresses set forth at the beginning of this
Agreement or such other address as either Party may specify in writing from time-to-time.

7.12   This Agreement may be signed in two or more counterparts.  When at least one such counterpart
has been signed by each Party, this Agreement shall be deemed to have been fully executed, each counterpart shall be
deemed to be an original, and all counterparts shall be deemed to be one and the same agreement.  The Parties agree that
the delivery of an executed copy of this Agreement by facsimile or email shall be legal and binding and shall have the same full
force and effect as if an original executed copy of this Agreement had been delivered.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the Effective Date.

	
CELGENE CORPORATION

By:/s/ Robert J. Hugin

Name:Robert J. Hugin

Title:Chief Executive Officer

Date:December 21, 2010
	
MMRGLOBAL, INC.

By:/s/ Robert H. Lorsch

Name:                                Robert H. Lorsch

Title:                     Chief Executive Officer

Date:December 21, 2010

   

   

MMR-Celgene Corporation Non-Exclusive License Agreement — CONFIDENTIAL  

  

[***]: Certain  confidential information contained in this document marked with [***] has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

EXHIBIT A

                  Non-Disclosure Agreement

   

   

   

   

   

   

   

   

MMR-Celgene Corporation Non-Exclusive License Agreement — CONFIDENTIAL  

  

[***]: Certain  confidential information contained in this document marked with [***] has been omitted and filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.MD Filed by Filing Services Canada Inc. 403-717-3898

	
Report of Independent Auditors

	
To the Shareholders of

Norsat International Inc.
 

    

We have audited the consolidated balance sheet of Norsat International Inc. as at December 31, 2009, and the consolidated statements of earnings, deficit, and comprehensive income, and cash flows for each of the years in the two year period ended December 31, 2009. These consolidated
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform an audit to obtain reasonable assurance whether the consolidated financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial
reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of
the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2009, and the results of its earnings,
deficit, and comprehensive income and its cash flows for each of the years in the two year period ended December 31, 2009 in conformity with Canadian generally accepted accounting principles, which differ in certain respects from United States
generally accepted accounting principles (see Note 25 to the consolidated financial statements).

As discussed in Note 2 to the consolidated financial statements, the Company changed its accounting for revenue recognition effective January 1, 2009.

 

 

 

	Vancouver, Canada March 11, 2010

		Ernst & Young LLP Chartered Accountants

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}]]